Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas
NCT06213571 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2026-01-09
Summary
This clinical trial studies how well a remotely delivered home-based exercise program for strength training works to positively impact endometrial cancer (EC) survivorship for patients with decreased cancer survivorship access. Cancer survivors in rural areas face barriers to supportive care, including geographic and environmental barriers to exercise and technology. Rural areas in the Midwest are underserved in terms of cancer care thus, it is essential to develop and test interventions that are scalable and can reach many individuals including those living in rural areas. Remotely-delivered exercise intervention approach allows for cancer survivors who may live far away from their primary treatment center to engage in supportive therapy via exercise interventions delivered in a sustainable context. In addition, historically black, hispanic and native endometrial cancer survivors have shorter survival and less access to survivorship care, so alternative models for healthcare delivery are needed in this underserved group. Information gained from this research may help determine whether utilizing a remotely delivered exercise program can positively impact EC survivorship for patients with decreased cancer survivorship access.
Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
- FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
- Stage IA Uterine Corpus Cancer AJCC v8
- Stage IB Uterine Corpus Cancer AJCC v8
Interventions
- OTHER
-
Exercise Counseling
Participate in exercise coaching sessions
- OTHER
-
Exercise Intervention
Participate in home-based exercise program
- OTHER
-
Health Promotion and Education
Receive resistance band and exercise booklets
- OTHER
-
Interview
Ancillary studies
- OTHER
-
Physical Performance Testing
Ancillary studies
- OTHER
-
Questionnaire Administration
Ancillary studies
- OTHER
-
Telemedicine
Participate in sessions remotely
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Amanika A Kumar, MD · Mayo Clinic in Rochester
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 50 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-22
- Primary Completion
- 2026-03-31
- Completion
- 2026-03-31
Countries
- United States
Study Locations
More Related Trials
-
Revealing Engagement Patterns Among Endometrial Cancer Patients
NCT05998798 ·Status: NOT_YET_RECRUITING
-
Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
NCT05047926 ·Status: COMPLETED ·Phase: NA
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112 ·Status: RECRUITING ·Phase: PHASE3
-
Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03685695 ·Status: COMPLETED ·Phase: PHASE2
-
PErsonalized TReatment for Endometrial Carcinoma
NCT05655260 ·Status: RECRUITING ·Phase: NA
-
Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer
NCT00004251 ·Status: COMPLETED ·Phase: PHASE2
-
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
NCT02657928 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
NCT03526432 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
NCT00575952 ·Status: COMPLETED ·Phase: PHASE1
-
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT03932409 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225 ·Status: RECRUITING ·Phase: PHASE3
-
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00006011 ·Status: COMPLETED ·Phase: PHASE3
-
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
NCT06483048 ·Status: RECRUITING ·Phase: PHASE1
-
Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia
NCT02342730 ·Status: COMPLETED ·Phase: NA
-
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
NCT03348631 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Improving the Treatment for Women With Early Stage Cancer of the Uterus
NCT01686126 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients
NCT02878980 ·Status: WITHDRAWN ·Phase: NA
-
Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers
NCT02412124 ·Status: TERMINATED ·Phase: NA
-
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
NCT00005612 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
NCT04049227 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01080521 ·Status: COMPLETED
-
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT04291612 ·Status: RECRUITING
-
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
NCT00282087 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352 ·Status: RECRUITING ·Phase: PHASE1/PHASE2